Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lina Shibib, Mo Al-Qaisi, Ahmed Ahmed, Alexander D Miras, David Nott, Marc Pelling, Stephen E Greenwald & Nicola Guess. (2022) Reversal and Remission of T2DM – An Update for Practitioners. Vascular Health and Risk Management 18, pages 417-443.
Read now
Read now
Desimira Mironova & Teodora Hanjieva-Darlenska. (2021) Effect of metformin and empagliflozin on adiponectin and leptin levels in rat model of hypo- and hyperthyroidism. Biotechnology & Biotechnological Equipment 35:1, pages 208-213.
Read now
Read now
Vasilios Tsimihodimos, Theodosios D. Filippatos & Moses S. Elisaf. (2017) Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 399-408.
Read now
Read now
Articles from other publishers (47)
Xiao Fan, Wensu Yuan, Weidong Huang & Zhi Lin. (2023) Recent progress in leptin signaling from a structural perspective and its implications for diseases. Biochimie 212, pages 60-75.
Crossref
Crossref
Raúl Lelio Sanz, Felipe Inserra, Sebastián García Menéndez, Luciana Mazzei, León Ferder & Walter Manucha. (2023) Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins. Current Hypertension Reports 25:6, pages 91-106.
Crossref
Crossref
Zsolt Szekeres, Barbara Sandor, Zita Bognar, Fadi H. J. Ramadan, Anita Palfi, Beata Bodis, Kalman Toth & Eszter Szabados. (2023) Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. International Journal of Molecular Sciences 24:5, pages 4405.
Crossref
Crossref
Simone A. Melander, Anna Katri, Morten A. Karsdal & Kim Henriksen. (2023) Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin. European Journal of Pharmacology 938, pages 175397.
Crossref
Crossref
Parisa Dana, Nasim Hayati Roodbari, Parichehreh Yaghmaei & Zahra Hajebrahimi. (2022) Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats. Frontiers in Endocrinology 13.
Crossref
Crossref
Hana Malínská, Martina Hüttl, Irena Marková, Denisa Miklánková, Silvie Hojná, František Papoušek, Jan Šilhavý, Petr Mlejnek, Josef Zicha, Jaroslav Hrdlička, Michal Pravenec & Ivana Vaněčková. (2022) Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein. Biomedicines 10:9, pages 2066.
Crossref
Crossref
Dina E. Al-Wakeel, Dalia H. El-Kashef & Manar A. Nader. (2022) Renoprotective effect of empagliflozin in cafeteria diet-induced insulin resistance in rats: Modulation of HMGB-1/TLR-4/NF-κB axis. Life Sciences 301, pages 120633.
Crossref
Crossref
Brent Deschaine, Sahil Verma & Hussein Rayatzadeh. (2022) Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?. Cardiac Failure Review 8.
Crossref
Crossref
Damáris Raissa dos Santos, Gabriela Alice Fiais, Henrique Arnaldo Oliveira, Tayná Buffulin Ribas, Rayne Oliveira Souza, Thaís Verônica Saori Tsosura, Doris Hissako Matsushita, Edilson Ervolino, Rita Cássia Menegati Dornelles, Ana Cláudia de Melo Stevanato Nakamune & Antonio Hernandes Chaves-Neto. (2022) Assessment of redox state and biochemical parameters of salivary glands in rats treated with anti-obesity drug sibutramine hydrochloride. Clinical Oral Investigations 26:9, pages 5833-5846.
Crossref
Crossref
Shufei Zeng, Denis Delic, Chang Chu, Yingquan Xiong, Ting Luo, Xiaoyi Chen, Mohamed M.S. Gaballa, Yao Xue, Xin Chen, Yaochen Cao, Ahmed A. Hasan, Kai Stadermann, Sandra Frankenreiter, Lianghong Yin, Bernhard K. Krämer, Thomas Klein & Berthold Hocher. (2022) Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet. Biomedicine & Pharmacotherapy 146, pages 112606.
Crossref
Crossref
Silvie Hojná, Hana Rauchová, Hana Malínská, Irena Marková, Martina Hüttl, František Papoušek, Michal Behuliak, Denisa Miklánková, Zdeňka Vaňourková, Jan Neckář, Michaela Kadlecová, Petr Kujal, Josef Zicha & Ivana Vaněčková. (2021) Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension. Biomedicine & Pharmacotherapy 144, pages 112246.
Crossref
Crossref
Jaroslava Trnovska, Petr Svoboda, Helena Pelantova, Marek Kuzma, Helena Kratochvilova, Barbora Judita Kasperova, Iveta Dvorakova, Katerina Rosolova, Hana Malinska, Martina Huttl, Irena Markova, Olena Oliyarnyk, Magdalena Melcova, Vojtech Skop, Milos Mraz, Sona Stemberkova-Hubackova & Martin Haluzik. (2021) Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress. International Journal of Molecular Sciences 22:19, pages 10606.
Crossref
Crossref
Arbinda Pokharel, Sudhamshu KC, Pukar Thapa, Niyanta Karki, Rupesh Shrestha, Bikash Jaishi & Mukesh S Paudel. (2021) The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease. Cureus.
Crossref
Crossref
Yuxin Chu, Cheng Zhang & Min Xie. (2021) Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts. Frontiers in Aging 2.
Crossref
Crossref
Ayaka Domon, Kentaro Katayama, Touko Sato, Yuki Tochigi, Hiroyuki Tazaki & Hiroetsu Suzuki. (2021) Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK). PLOS ONE 16:5, pages e0251135.
Crossref
Crossref
Kenji Takeda, Hiraku Ono, Ko Ishikawa, Tomohiro Ohno, Jin Kumagai, Hidetoshi Ochiai, Ai Matumoto, Hidetaka Yokoh, Yoshiro Maezawa & Koutaro Yokote. (2021) Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats. BMJ Open Diabetes Research & Care 9:1, pages e002104.
Crossref
Crossref
Ghulam Md. Ashraf, Badrah S. Alghamdi, Fahad S. Alshehri, Mohammad Z. Alam, Haythum O. Tayeb & Frank I. Tarazi. (2021) Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats. Current Gene Therapy 21:1, pages 53-59.
Crossref
Crossref
Zaid H. Maayah, Mourad Ferdaoussi, Shingo Takahara, Shubham Soni & Jason R. B. Dyck. (2020) Empagliflozin suppresses inflammation and protects against acute septic renal injury. Inflammopharmacology 29:1, pages 269-279.
Crossref
Crossref
Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann, Jean-Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel & Valérie B. Schini-Kerth. (2020) Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovascular Diabetology 19:1.
Crossref
Crossref
L. D’Elia, A. Giaquinto, F. P. Cappuccio, R. Iacone, O. Russo, P. Strazzullo & F. Galletti. (2019) Circulating leptin is associated with serum uric acid level and its tubular reabsorption in a sample of adult middle-aged men. Journal of Endocrinological Investigation 43:5, pages 587-593.
Crossref
Crossref
Atsushi Kuno, Yukishige Kimura, Masashi Mizuno, Hiroto Oshima, Tatsuya Sato, Norihito Moniwa, Marenao Tanaka, Toshiyuki Yano, Masaya Tanno, Takayuki Miki & Tetsuji Miura. (2020) Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats. Scientific Reports 10:1.
Crossref
Crossref
Hoda E. Mohamed, Mervat E. Asker, Mohammed M. Keshawy, Rehab A. Hasan & Yasmin K. Mahmoud. (2020) Inhibition of tumor necrosis factor-α enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance. Molecular and Cellular Biochemistry 466:1-2, pages 45-54.
Crossref
Crossref
Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li & Tong Liu. (2019) Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovascular Diabetology 18:1.
Crossref
Crossref
R. Loera‐Valencia, A. Cedazo‐Minguez, P.A. Kenigsberg, G. Page, A.I. Duarte, P. Giusti, M. Zusso, P. Robert, G. B. Frisoni, Annamaria Cattaneo, M. Zille, J. Boltze, N. Cartier, L. Buee, G. Johansson & B. Winblad. (2019) Current and emerging avenues for Alzheimer's disease drug targets. Journal of Internal Medicine 286:4, pages 398-437.
Crossref
Crossref
L. D'Elia, P. Strazzullo, R. Iacone, O. Russo & F. Galletti. (2019) Leptin levels predict the development of insulin resistance in a sample of adult men–The Olivetti Heart Study. Nutrition, Metabolism and Cardiovascular Diseases 29:1, pages 39-44.
Crossref
Crossref
Rana Assaly, Diane Gorny, Sandrine Compagnie, Eric Mayoux, Jacques Bernabe, Laurent Alexandre, François Giuliano & Delphine Behr-Roussel. (2018) The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes. The Journal of Sexual Medicine 15:9, pages 1224-1234.
Crossref
Crossref
Atsuo Tahara, Yoshinori Kondo, Toshiyuki Takasu & Hiroshi Tomiyama. (2018) Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats. Biomedicine & Pharmacotherapy 105, pages 1033-1041.
Crossref
Crossref
Yumiko Chiba, Tetsuya Yamada & Hideki Katagiri. (2018) Dapagliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, Acutely Reduces Energy Expenditure in Brown Adipose Tissue <i>via</i> Neural Signals in Mice中枢末梢臓器間連関を介したSGLT2阻害薬によるエネルギー代謝調節機構. YAKUGAKU ZASSHI 138:7, pages 945-954.
Crossref
Crossref
Niki Katsiki, Dimitri P Mikhailidis & Maciej Banach. (2018) Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacologica Sinica 39:7, pages 1176-1188.
Crossref
Crossref
Milton Packer. (2018) Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes, Obesity and Metabolism 20:6, pages 1361-1366.
Crossref
Crossref
Paula Gondim, Priscila Rosa, Daniel Okamura, Viviam Silva, Eric Andrade, Daniel Biihrer & Luciano Pereira. (2018) Benefits of Fish Oil Consumption over Other Sources of Lipids on Metabolic Parameters in Obese Rats. Nutrients 10:1, pages 65.
Crossref
Crossref
Mohamed Mahmoudi, Kamel Charradi, Ferid Limam & Ezzedine Aouani. (2018) Grape seed and skin extract as an adjunct to xenical therapy reduces obesity, brain lipotoxicity and oxidative stress in high fat diet fed rats. Obesity Research & Clinical Practice 12:1, pages 115-126.
Crossref
Crossref
Flavio A. Cadegiani, Gustavo C. Diniz & Gabriella Alves. (2017) Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. BMC Obesity 4:1.
Crossref
Crossref
. (2017) Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine 377:22, pages 2195-2198.
Crossref
Crossref
Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschof, Maximilian Kopp, Ute Gödtel-Armbrust, Ning Xia, Huige Li, Eberhard Schulz, Karl J. Lackner, Leszek Wojnowski, Serge P. Bottari, Philip Wenzel, Eric Mayoux, Thomas Münzel & Andreas Daiber. (2017) The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biology 13, pages 370-385.
Crossref
Crossref
Toshiyuki TakasuYuka HayashizakiJiro HirosumiHideaki MinouraNobuaki AminoEiji KurosakiShoji Takakura. (2017) The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto–Kakizaki Rats. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 40:5, pages 675-680.
Crossref
Crossref
Rhodri J King & Ramzi A Ajjan. (2016) Vascular risk in obesity: Facts, misconceptions and the unknown. Diabetes and Vascular Disease Research 14:1, pages 2-13.
Crossref
Crossref
Eric Andrade, Andressa Lima, Ingrid Nunes, Débora Orlando, Paula Gondim, Márcio Zangeronimo, Fernando Alves & Luciano Pereira. (2016) Exercise and Beta-Glucan Consumption (Saccharomyces cerevisiae) Improve the Metabolic Profile and Reduce the Atherogenic Index in Type 2 Diabetic Rats (HFD/STZ). Nutrients 8:12, pages 792.
Crossref
Crossref
Teruo Jojima, Takanori Tomotsune, Toshie Iijima, Kazumi Akimoto, Kunihiro Suzuki & Yoshimasa Aso. (2016) Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetology & Metabolic Syndrome 8:1.
Crossref
Crossref
Norihisa Nishimura, Mitsuteru Kitade, Ryuichi Noguchi, Tadashi Namisaki, Kei Moriya, Kosuke Takeda, Yasushi Okura, Yosuke Aihara, Akitoshi Douhara, Hideto Kawaratani, Kiyoshi Asada & Hitoshi Yoshiji. (2016) Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats. Journal of Gastroenterology 51:12, pages 1141-1149.
Crossref
Crossref
Yumiko Chiba, Tetsuya Yamada, Sohei Tsukita, Kei Takahashi, Yuichiro Munakata, Yuta Shirai, Shinjiro Kodama, Yoichiro Asai, Takashi Sugisawa, Kenji Uno, Shojiro Sawada, Junta Imai, Kazuhiro Nakamura & Hideki Katagiri. (2016) Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLOS ONE 11:3, pages e0150756.
Crossref
Crossref
Anna Solini. (2016) Extra-glycaemic properties of empagliflozin. Diabetes/Metabolism Research and Reviews 32:3, pages 230-237.
Crossref
Crossref
S. P. Rajeev, D. J. Cuthbertson & J. P. H. Wilding. (2016) Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes, Obesity and Metabolism 18:2, pages 125-134.
Crossref
Crossref
Martin C. Michel, Eric Mayoux & Volker Vallon. (2015) A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn-Schmiedeberg's Archives of Pharmacology 388:8, pages 801-816.
Crossref
Crossref
Sung Mee LeeYun Hwan KangKyoung Kon KimTae Woo KimMyeon Choe. (2015)
A study of the lipoprotein lipase inhibitory mechanism of
Poncirus trifoliata
water extracts
. Journal of Nutrition and Health 48:1, pages 9.
Crossref
Crossref
Yun Hwan KangKyoung Kon KimDae Jung KimMyeon Choe. (2015)
Antiobesity effects of the water-soluble fraction of the ethanol extract of
Smilax china
L. leaf in 3T3-L1 adipocytes
. Nutrition Research and Practice 9:6, pages 606.
Crossref
Crossref
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova, Anna Gottschlich, Sebastian Steven, Eberhard Schulz, Serge P. Bottari, Eric Mayoux, Thomas Münzel & Andreas Daiber. (2014) The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity. PLoS ONE 9:11, pages e112394.
Crossref
Crossref